{
    "clinical_study": {
        "@rank": "141222", 
        "arm_group": [
            {
                "arm_group_label": "Tea Treatment Group", 
                "arm_group_type": "Experimental", 
                "description": "5 cups brewed tea beverage per day for 28 days, brewed from 700 mg of black tea solids per cup"
            }, 
            {
                "arm_group_label": "Placebo Group", 
                "arm_group_type": "Placebo Comparator", 
                "description": "5 cups tea-like placebo per day for 28 days. Placebo was exactly matched to tea except for flavonoid composition. Placebo was flavonoid-free."
            }
        ], 
        "brief_summary": {
            "textblock": "A diet-controlled clinical trial which attempts to provide estimates of the effect of black\n      tea consumption on serum lipids under tightly controlled conditions, including a controlled\n      diet. Mildly hypercholesterolemic individuals (total cholesterol levels between 4.9 and 6.7\n      mmol/L, 190 and 260 mg/dl), non-smoking, chronic disease-free individuals were enrolled in a\n      15-week, double blind, randomized crossover trial, during which they consumed a controlled\n      low-flavonoid diet plus 5 cups of black tea or a tea-like placebo over two 4-week treatment\n      periods."
        }, 
        "brief_title": "Effects of Black Tea Intake on Serum Lipids", 
        "condition": "Hypercholesterolemia", 
        "condition_browse": {
            "mesh_term": "Hypercholesterolemia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  between 45-65 years old\n\n          -  mildly hypercholesterolemic (total cholesterol levels between 4.9 and 6.7 mmol/L, 190\n             and 260 mg/dl)\n\n          -  high-density lipoprotein cholesterol (HDL-C) between 0.9 and 1.6 mmol/L (35 and 65\n             mg/dl)\n\n          -  triglyceride (TG) concentrations below 6.8 mmol/L (600 mg/dl)\n\n          -  habitually consumed a typical American diet with low dietary flavonoid intake (<4\n             one-half cup servings of fruits and vegetables/day) and low intake (<1 serving/day)\n             of soy-rich foods, nuts, herbs, and spices (besides salt and pepper)\n\n          -  aspartate aminotransferase (AST) between 0 and 55 mg/L\n\n          -  creatinine between 70.7 and 150.3 mmol/L (0.8 and 1.7 mg/dl)\n\n          -  glucose between 3.3 and 6.4 mmol/L (60 and 115 mg/dl)\n\n        Exclusion Criteria:\n\n          -  current smoker\n\n          -  usage of high amounts of antioxidant vitamin supplements (>3 times the Recommended\n             Dietary Allowance (RDA) of vitamins E, C, and selenium, or >10 mg/day of beta\n             carotene)\n\n          -  had been diagnosed with diabetes, coagulation disorders, chronic pulmonary disease,\n             current active malignancy, renal disease requiring dialysis, malabsorption, or\n             gastrointestinal disorders, or had a history of cardiovascular disease.\n\n          -  antihypertensive, immunosuppressive, cholesterol lowering, or anticoagulant\n             medications\n\n          -  consuming >3 servings of alcohol daily\n\n          -  Pre-menopausal (women)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "45 Years"
        }, 
        "enrollment": {
            "#text": "57", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01882283", 
            "org_study_id": "10205345-A2", 
            "secondary_id": "M01RR000400"
        }, 
        "intervention": {
            "arm_group_label": [
                "Tea Treatment Group", 
                "Placebo Group"
            ], 
            "description": "This intervention was a crossover trial, during which each patient experienced both placebo and tea treatment arms", 
            "intervention_name": "Tea Treatment Group", 
            "intervention_type": "Dietary Supplement", 
            "other_name": "Brewed black tea beverage"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "serum lipids", 
            "cholesterol", 
            "serum cholesterol", 
            "black tea", 
            "flavonoids", 
            "crossover trial", 
            "randomized control trial", 
            "diet controlled"
        ], 
        "lastchanged_date": "June 17, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Minneapolis", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55454"
                }, 
                "name": "General Clinical Research Center, University of Minnesota"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effects of Black Tea Intake on Serum Lipids in Mildly Hypercholesterolemic Adults A Randomized Diet-controlled Crossover Trial", 
        "overall_official": {
            "affiliation": "University of Minnesota - Clinical and Translational Science Institute", 
            "last_name": "Myron Gross, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2004", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Serum lipid levels (total cholesterol, LDL-C, HDL-C, triglycerides, LDL-C+HDL-C fraction, LDL-C/HDL-C ratio) were assessed at the end of a 28-day treatment period", 
            "measure": "Serum lipid levels", 
            "safety_issue": "No", 
            "time_frame": "4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01882283"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "University of Minnesota - Clinical and Translational Science Institute", 
        "sponsors": {
            "collaborator": {
                "agency": "National Center for Research Resources (NCRR)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "University of Minnesota - Clinical and Translational Science Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2002", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}